Experimental therapy stopped the metastasis of breast and ovarian cancers in lab mice, pointing toward a safe and effective alternative to chemotherapy.
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the bloodstream and start aggressive new growths elsewhere in the body.
This process, known as metastasis, can cause cancer to spread with deadly effect.
“The majority of patients who succumb to cancer fall prey to metastatic forms of the disease,” said Jennifer Cochran, an associate professor of bioengineering who describes a new therapeutic approach in Nature Chemical Biology.
Today doctors try to slow or stop metastasis with chemotherapy, but these treatments are unfortunately not very effective and have severe side effects.
The Stanford team seeks to stop metastasis, without side effects, by preventing two proteins – Axl and Gas6 – from interacting to initiate the spread of cancer.
Axl proteins stand like bristles on the surface of cancer cells, poised to receive biochemical signals from Gas6 proteins.
When two Gas6 proteins link with two Axls, the signals that are generated enable cancer cells to leave the original tumor site, migrate to other parts of the body and form new cancer nodules.
To stop this process Cochran used protein engineering to create a harmless version of Axl that acts like a decoy. This decoy Axl latches on to Gas6 proteins in the bloodstream and prevents them from linking with and activating the Axls present on cancer cells.
In collaboration with Professor Amato Giaccia, who leads the Radiation Biology Program in the Stanford Cancer Center, the researchers gave intravenous treatments of this bioengineered decoy protein to mice with aggressive breast and ovarian cancers.
Mice in the breast cancer treatment group had 78 percent fewer metastatic nodules than untreated mice. Mice with ovarian cancer had a 90 percent reduction in metastatic nodules when treated with the engineered decoy protein.
“This is a very promising therapy that appears to be effective and nontoxic in preclinical experiments,” Giaccia said. “It could open up a new approach to cancer treatment.”
The Latest on: Alternative to chemotherapy
via Google News
The Latest on: Alternative to chemotherapy
- Tauranga mother dying of cancer resorts to alternative treatment in Mexicoon November 22, 2019 at 8:21 am
These are the desperate words of a Tauranga mother with terminal metastatic breast cancer who is flying to Mexico to undergo an alternative treatment in the hope it will give her more time. Matua ...
- Using Artificial Intelligence to determine whether immunotherapy is workingon November 22, 2019 at 7:22 am
Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune ... Our goal and mission ...
- Breast and kidney cancer drugs approved on NHS Scotlandon November 22, 2019 at 5:39 am
Two new cancer treatment options have been accepted for use in Scotland for some patients living ... "The approval of ribociclib with fulvestrant offers an alternative to two other drug combinations ...
- Hope4Cancer™ Treatment Centers To Launch 'Eight Days' The First Reality Show About Alternative Ways To Fight Canceron November 20, 2019 at 3:00 am
"We partnered with film producer, Charles Mattocks, to help us share our patients' stories, because we know of his work as a health advocate and appreciate his passion for investigative storytelling," ...
- New technology may offer alternative means of profiling tissueson November 19, 2019 at 10:30 am
Current cancer treatment courses often begin with tissue biopsies ... from Tel Aviv University (TAU), Herzliya Interdisciplinary (IDC), and Technion-Israel Institute of Technology may soon offer an ...
- Medicare Out-Of-Pocket Costs For Cancer Treatment Every Retiree Should Knowon November 18, 2019 at 5:04 am
That is not always true. Yes, Medicare with a Medigap supplement does a great job of covering the direct costs of things like chemotherapy and infusions, but there are indirect costs that are rarely ...
- Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysison November 14, 2019 at 3:06 am
and uses the GR pathway as an alternative pathway to maintain their viability. In addition, ARV7 may play an important role in acquiring resistance to chemotherapy in CRPC patients. Moreover, the ARV7 ...
- CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Canceron November 13, 2019 at 4:17 pm
Under this protocol, patients with locally recurrent or metastatic triple-negative breast cancer who had progressed within six months or less on latest chemotherapy will receive leronlimab (PRO ...
- Teva Pharmaceuticals To Resume Production Of Scarce Childhood Cancer Drug Vincristineon November 13, 2019 at 12:24 pm
The statement from Teva USA posted on their Twitter page: Statement from Teva Pharmaceuticals USA Most children with cancer are treated with a cocktail of chemotherapy agents, many of which have no ...
- MU researchers continue to retrain immune system to fight cancer after receiving a $3.7 million granton November 11, 2019 at 4:49 pm
This would serve as an alternative to more conventional approaches like radiotherapy and chemotherapy, that could improve the outcomes for patients not responding to these treatments alone. A $3.7 ...
via Bing News